ICPT - インタ―セプト・ファ―マシュ―ティカルズ (Intercept Pharmaceuticals Inc.) インタ―セプト・ファ―マシュ―ティカルズ

 ICPTのチャート


 ICPTの企業情報

symbol ICPT
会社名 Intercept Pharmaceuticals Inc (インタ―セプト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インターセプト・ファーマシューティカルズ(Intercept Pharmaceuticals Inc.)は胆汁酸化学を利用して、慢性肝疾患を治療する治療薬の開発と商業化を中心とするバイオ医薬品会社。同社の製品候補である「オベチコール酸(OCA)」は、天然に存在するヒトの胆汁酸に基づく構造を有する化学物質である胆汁酸アナログ。同社は不十分な応答を持っている患者、またはケア治療の標準を容認することができないため、追加的な治療を必要とする患者のための二次治療として、原発性胆汁性肝硬変(PBC)のために最初に「OCA」を開発している。 同社はPOISE試験と呼ばれるPBCでOCAの第Ⅲ相臨床試験を行い、POISE試験は米国と欧州で規制当局の承認を求めるための基礎となる。平成24年12月19日現在、同社は217人の患者とPOISE試験への登録を完了した。   インタ―セプト・ファ―マシュ―ティカルズは、米国のバイオ医薬品メ―カ―。独自の胆汁酸化学を利用し、慢性の肝臓疾患を治療する薬品の開発、商品化に注力する。同社の製品候補オベチコ―ル酸(OCA)は、胆汁酸に類似した化学物質であり、原発性胆汁性肝硬変のために開発、反応の低い患者などの治療として使われる。米国全土の消費者を対象に、事業を展開。   Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
本社所在地 10 Hudson Yards 37th FL New York NY 10001 USA
代表者氏名 Paolo Fundaro パオロ・ファナロ
代表者役職名 Independent Chairman of the Board
電話番号 +1 646-747-1000
設立年月日 37500
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数 507人
url www.interceptpharma.com
nasdaq_url https://www.nasdaq.com/symbol/icpt
adr_tso
EBITDA EBITDA(百万ドル) -311.21800
終値(lastsale) 108.02
時価総額(marketcap) 3193577165.68
時価総額 時価総額(百万ドル) 2829.932
売上高 売上高(百万ドル) 158.55900
企業価値(EV) 企業価値(EV)(百万ドル) 2654.894
当期純利益 当期純利益(百万ドル) -340.65600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intercept Pharmaceuticals Inc revenues increased 53% to $79.5M. Net loss decreased 11% to $156.8M. Revenues reflect Licensing revenue increase of 36% to $1.2M. Lower net loss reflects Stock-based Compensation in R&D decrease of 26% to $7M (expense) Other income net increase of 44% to $3.5M (income) General_Administrative decrease of 1% to $108.3M (expense).

 ICPTのテクニカル分析


 ICPTのニュース

   How Much Of Intercept Pharmaceuticals, Inc. (NASDAQ-ICPT) Do Institutions Own?  2021/06/24 07:37:08 Simply Wall St
How Much Of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Do Institutions Own? Simply Wall St
   Intercept to Present at the Raymond James 2021 Human Health Innovation Conference  2021/06/15 12:00:00 Intrado Digital Media
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the Raymond James 2021 Human Health Innovation Conference on Tuesday, June 22, 2021 at 1:20 p.m. ET.
   Asensus Surgical to join Russell Microcap Index, while Sorrento Therapeutics to see deletion  2021/06/14 19:29:28 Seeking Alpha
   Intercept Pharmaceuticals Stock Gives Every Indication Of Being Possible Value Trap  2021/06/10 16:00:38 GuruFocus
Related Stocks: ICPT ,
   Intercept names Michelle Berrey as chief medical officer  2021/06/09 12:43:49 Seeking Alpha
   The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs  2021/05/27 12:23:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB ) Nuvation Bio Inc. (NYSE: NUVB ) PDS Biotechnology Corporation (NASDAQ: PDSB ) Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS ) PLx Pharma Inc. (NASDAQ: PLXP ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 26) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Axcella Health Inc. (NASDAQ: AXLA ) Black Diamond Therapeutics, Inc. (NASDAQ: BDTX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Coherus BioSciences, Inc. (NASDAQ: CHRS ) Evofem Biosciences, Inc. (NASDAQ: EVFM ) Impel NeuroPharma, Inc. (NASDAQ: IMPL ) IMV Inc. (NASDAQ: IMV ) Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT ) Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA ) Larimar Therapeutics, Inc. (NASDAQ: LRMR ) ( reacted to a clinical hold imposed on Phase 1 study of CTI-1601 in Friedreich ataxia) Spruce Biosciences, Inc. (NASDAQ: SPRB ) Travere Therapeutics, Inc. (NASDAQ: TVTX ) (flagged a delay in regulatory filing for drug to treat kidney scarring) Viking Therapeutics, Inc. (NASDAQ: VKTX ) Stocks In Focus Vir-GlaxoSmithKline's Antibody Treatment Approved For Mild-To-Moderate COVID-19 GlaxoSmithKline plc (NYSE: GSK ) and Vir Biotechnology, Inc. (NASDAQ: VIR ) said the FDA granted an emergency use authorization for sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients12 years of age and older weighing at least 40 kg who have tested positive for SARS-CoV-2 and who are at high risk for progression to severe COVID-19, including hospitalization or death.
   The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron  2021/05/12 12:57:17 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ: HOOK ) Novo Nordisk A/S (NYSE: NVO ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 11) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) ADC Therapeutics SA (NYSE: ADCT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akouos, Inc. (NASDAQ: AKUS ) (reacted to presentation of non-clinical data on gene therapy candidates at the American Society of Gene and Cell Therapy meeting) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aptinyx Inc. (NASDAQ: APTX ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) (reacted to its first-quarter results) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings  2021/05/11 11:54:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV ) - Its Allergan subsidiary announced a deal to buy Soliton, Inc. (NASDAQ: SOLY ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Quest Diagnostics Incorporated (NYSE: DGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 10) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 4D pharma plc (NASDAQ: LBPS ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Acutus Medical, Inc. (NASDAQ: AFIB ) Adagene Inc. (NASDAQ: ADAG ) Adaptive Biotechnologies Corporation (NASDAQ: ADPT ) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Athersys, Inc. (NASDAQ: ATHX ) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) (reacted to publication of positive results for a late-stage asset in lupus nephritis) Autolus Therapeutics plc (NASDAQ: AUTL ) AVROBIO, Inc.
   Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju Acquires 147,000 Shares  2021/03/13 01:24:33 Watchlist News
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju acquired 147,000 shares of the firm’s stock in a transaction that occurred on Friday, March 12th. The shares were bought at an average cost of $21.29 per share, for a total transaction of $3,129,630.00. Following the purchase, the director now owns 23,121 shares of the company’s stock, valued […]
   The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study  2021/03/05 13:15:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4) AtriCure, Inc. (NASDAQ: ATRC ) Five Prime Therapeutics, Inc. ( NASDAQ: FPRX) - announced a deal to be bought by Amgen Inc. (NASDAQ: AMGN ) for $1.9 billion Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 4) AbCellera Biologics Inc. (NASDAQ: ABCL ) Acutus Medical, Inc. (NASDAQ: AFIB ) ADC Therapeutics SA (NYSE: ADCT ) Aptose Biosciences Inc. (NASDAQ: APTO ) Assembly Biosciences, Inc. (NASDAQ: ASMB ) Athenex, Inc. (NASDAQ: ATNX ) Biophytis SA (NASDAQ: BPTS ) Bioventus Inc. (NASDAQ: BVS ) Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ) BriaCell Therapeutics Corp. (NASDAQ: BCTX ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) Dyne Therapeutics, Inc. (NASDAQ: DYN ) (reacted to fourth-quarter results) Epizyme, Inc. (NASDAQ: EPZM ) Freeline Therapeutics Holdings plc (NASDAQ: FRLN ) Galecto, Inc. (NASDAQ: GLTO ) Inhibikase Therapeutics, Inc.
   The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida  2021/02/26 13:16:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 25) Acutus Medical Inc (NASDAQ: AFIB ) Aptose Biosciences Inc (NASDAQ: APTO ) Bioventus Class A Ord Shs (Proposed) (NASDAQ: BVS ) Epizyme Inc (NASDAQ: EPZM ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) (reacted to fourth-quarter results) Lucira Health Inc (NASDAQ: LHDX ) Opthea Spon American Depositary Receipts Representing 8 Ord Shs (NASDAQ: OPT ) Sensei Biotherapeutics Inc (NASDAQ: SNSE ) Virios Therapeutics LLC (NASDAQ: VIR ) Voyager Therapeutics Inc (NASDAQ: VYGR ) Stocks In Focus Tricida Receives Appeals Denied Letter From FDA Regarding Veverimer Tricida Inc (NASDAQ: TCDA ) said it has received an appeal denied letter, or ADL, from the FDA's Office of New Drugs in response to a formal dispute resolution request submitted in December regarding its NDA for veverimer, which is being evaluated as a treatment option for metabolic acidosis in chronic kidney disease patients.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インタ―セプト・ファ―マシュ―ティカルズ ICPT Intercept Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)